Honey bee venom allergen (HBV allergen)

Honey bee venom allergen refers to a collection of proteins and peptides found in the venom of the honey bee (Apis mellifera) that are capable of eliciting Type I hypersensitivity reactions in sensitized individuals. The most clinically significant components include Phospholipase A2 (Api m 1), Hyaluronidase (Api m 2), Acid phosphatase (Api m 3), and Icarapin (Api m 10), which often act as enzymes or membrane-disrupting agents. These allergens are the primary targets for venom immunotherapy (VIT), a disease-modifying treatment designed to induce immunological tolerance and prevent life-threatening anaphylaxis. VIT works by shifting the immune response from a Th2-mediated allergic state to a Th1/Treg-mediated protective state, characterized by the induction of "blocking" IgG4 antibodies and the desensitization of mast cells and basophils. Monitoring efficacy involves tracking specific IgE and IgG4 levels, while baseline tryptase levels are used to assess the risk of severe reactions during treatment. Despite its high success rate, challenges remain regarding the risk of systemic adverse reactions during therapy and the underrepresentation of certain allergens like Api m 10 in standard therapeutic extracts.

Other names

Apis mellifera venom allergenBee venom allergenApitoxin allergenHBV allergen

Induction of immunological tolerance through allergen-specific immunotherapy (AIT), which promotes the expansion of regulatory T cells (Tregs), increases protective IgG4 blocking antibodies, and reduces IgE-mediated activation of mast cells and basophils.